Clinicians and patients should avoid using compounded GLP-1 products that are not FDA-approved, the American Diabetes Association wrote in a guidance statement published Dec. 2 in Diabetes Care.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
